CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1 Study of Selinexor (KPT-330), A Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02323880
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:58.870274+00:00
Published At: 2024-01-02T00:00:00+00:00
Record Updated At: 2025-01-14
Results Posted At: 2024-01-02
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Malignant Glioma", "Recurrent Brain Neoplasm", "Recurrent Childhood Central Nervous System Neoplasm", "Recurrent Childhood Glioblastoma", "Recurrent Lymphoma", "Recurrent Malignant Solid Neoplasm", "Refractory Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Primary Central Nervous System Neoplasm", "WHO Grade 3 Glioma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-01-14"
protocolSection.identificationModule.nctId: "NCT02323880"
protocolSection.identificationModule.officialTitle: "A Phase 1 Study of Selinexor (KPT-330), A Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2024-01-02"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.